锂盐联合丙戊酸与锂盐联合卡马西平治疗年轻1型双相障碍患者的随机对照试验:LICAVAL研究
LICAVAL是一项在巴西圣保罗某三级医院开展的随机、单中心、开放标签、平行组试验,于2009年1月至2012年12月纳入18至35岁1型双相障碍患者,随访2年,比较锂盐联合丙戊酸(Li/VPA)与锂盐联合卡马西平(Li/CBZ)的疗效与耐受性。结果显示两组在CGI-BP评分及其他结局上均无组间差异,仅治疗第一周副作用存在显著差异且Li/VPA组更多,Li/VPA组体重增加(+2.1 kg)而Li/CBZ组体重轻度下降(-0.2 kg)。作者认为两方案疗效与耐受性相似,但Li/CBZ长期可能具有代谢优势。
要点
- 两组在CGI-BP评分上无组间差异(P=0.326),其他结局亦无差异。
- 仅治疗第一周副作用存在显著组间差异(P=0.021),Li/VPA组更多。
- Li/VPA组体重增加(+2.1 kg),Li/CBZ组体重轻度下降(-0.2 kg)。
核心结论
- 本研究提示Li/VPA与Li/CBZ在双相障碍中疗效和耐受性相似,但Li/CBZ长期可能具有代谢优势。
研究设计与样本
- LICAVAL为随机、单中心、开放标签、平行组试验,于2009年1月至2012年12月在巴西圣保罗某三级医院开展。
- 共64例18至35岁1型双相障碍患者,36例分配至Li/VPA组,28例分配至Li/CBZ组,随访2年。
- 主要结局为急性期达到缓解和维持期维持缓解的受试者数量,采用双因素重复测量方差分析和Cohen's d估计效应量。
主要发现
- 样本以女性为主(66.6%),平均年龄27.8岁;27例(45.0%)为抑郁,17例(28.3%)为躁狂/轻躁狂,16例(26.7%)为混合状态。
- CGI-BP评分无组间差异(P=0.326),其他任何结局亦无组间差异。
- 副作用仅在治疗第一周存在显著组间差异(P=0.021),Li/VPA组副作用更多。
- Li/VPA组体重增加(+2.1 kg),而Li/CBZ组体重轻度下降(-0.2 kg)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of bipolar disorder (BD) usually requires drug combinations. Combinations of lithium plus valproic acid (Li/VPA) and lithium plus carbamazepine (Li/CBZ) are used in clinical practice but were not previously compared in a head-to-head trial. OBJECTIVE: The objective of this trial was to compare the efficacy and tolerability of Li/VPA versus Li/CBZ in treating type 1 BD in any phase of illness in young individuals. METHODS: LICAVAL was a randomized, unicenter, open-label, parallel-group trial that was conducted from January 2009 to December 2012 in a tertiary hospital in São Paulo, Brazil. Participants were between 18 and 35 years old and were followed up for 2 years. Our primary outcome was the number of participants achieving/maintaining response and remission during the acute and maintenance phases of BD treatment, respectively. Other outcomes assessed were symptom severity and adverse events throughout the study. In the analysis of the primary outcome, we compared groups by using a two-way repeated measures analysis of variance and estimated effect sizes by using Cohen's d. RESULTS: Of our 64 participants, 36 were allocated to Li/VPA and 28 to Li/CBZ. Our sample was composed predominantly of females (66.6%) and the average age was 27.8 years. A total of 27 (45.0%) participants had depression, 17 (28.3%) had mania/hypomania, and 16 (26.7%) had a mixed state. We found no between-group differences in CGI-BP (Clinical Global Impression Scale modified for use in bipolar disorder) scores (P = 0.326) or in any other outcome. Side effects differed significantly between groups only in the first week of treatment (P = 0.021), and there were more side effects in the Li/VPA group. Also, the Li/VPA group gained weight (+2.1 kg) whereas the Li/CBZ group presented slight weight loss (-0.2 kg). CONCLUSION: Our study suggests that Li/VPA and Li/CBZ have similar efficacy and tolerability in BD but that Li/CBZ might have metabolic advantages in the long term. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00976794 . Registered on September 9, 2009.
引用
- Missio G, Moreno DH, Demetrio FN, et al. A randomized controlled trial comparing lithium plus valproic acid versus lithium plus carbamazepine in young patients with type 1 bipolar disorder: the LICAVAL study. Trials. 2019. PMID: 31655626. doi:10.1186/s13063-019-3655-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。